Alnylam Pharmaceuticals (ALNY) Stock Forecast & Price Target

$414.62 +12.82 (+3.19%)

As of 10:56 AM Eastern

Alnylam Pharmaceuticals - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 27 Analyst Ratings

Sell
0

Hold
4

Buy
23

Based on 27 Wall Street analysts who have issued ratings for Alnylam Pharmaceuticals in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 27 analysts, 4 have given a hold rating, and 23 have given a buy rating for ALNY.

Consensus Price Target

$396.04
-4.48% Downside

According to the 27 analysts' twelve-month price targets for Alnylam Pharmaceuticals, the average price target is $396.04. The highest price target for ALNY is $550.00, while the lowest price target for ALNY is $220.00. The average price target represents a forecasted downside of -4.48% from the current price of $414.62.

Get the Latest News and Ratings for ALNY and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Alnylam Pharmaceuticals and its competitors.

ALNY Analyst Ratings Over Time

Type	Current Forecast 8/4/24 to 8/4/25	1 Month Ago 7/5/24 to 7/5/25	3 Months Ago 5/6/24 to 5/6/25	1 Year Ago 8/5/23 to 8/4/24
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	23 Buy rating(s)	20 Buy rating(s)	21 Buy rating(s)	16 Buy rating(s)
Hold	4 Hold rating(s)	3 Hold rating(s)	4 Hold rating(s)	8 Hold rating(s)
Sell	0 Sell rating(s)	1 Sell rating(s)	1 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$396.04	$340.00	$319.17	$269.32
Forecasted Upside	-4.48% Downside	2.43% Upside	18.29% Upside	-1.00% Downside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy

ALNY Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

ALNY Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Alnylam Pharmaceuticals Stock vs. The Competition

Type	Alnylam Pharmaceuticals	Medical Companies	S&P 500
Consensus Rating Score	2.85	2.81	2.53
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	-3.87% Downside	10,031.61% Upside	13.76% Upside
News Sentiment Rating	Positive News See Recent ALNY News	Neutral News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
8/4/2025	Oppenheimer 2 of 5 stars	Leland Gershell Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Market Perform ➝ Outperform	$490.00	+21.95%
8/4/2025	Wolfe Research 3 of 5 stars	Andy Chen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Underperform ➝ Peer Perform
8/1/2025	Scotiabank 5 of 5 stars	Greg Harrison Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Sector Outperform ➝ Sector Outperform	$342.00 ➝ $450.00	+12.00%
8/1/2025	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Eliana Merle Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Buy ➝ Buy	$403.00 ➝ $550.00	+38.02%
8/1/2025	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Whitney Ijem Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Buy ➝ Buy	$390.00 ➝ $415.00	+4.88%
8/1/2025	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Tiago Fauth Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Equal Weight ➝ Equal Weight	$333.00 ➝ $395.00	-0.23%
8/1/2025	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Gena Wang Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Overweight ➝ Overweight	$329.00 ➝ $460.00	+17.28%
8/1/2025	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Edward Tenthoff Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Overweight ➝ Overweight	$304.00 ➝ $449.00	+14.47%
8/1/2025	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Michael Ulz Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Equal Weight ➝ Equal Weight	$312.00 ➝ $405.00	+3.25%
8/1/2025	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Keay Nakae Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Buy ➝ Buy	$325.00 ➝ $400.00	+1.98%
Get the Latest News and Ratings for ALNY and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Alnylam Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.
7/31/2025	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Joseph Stringer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Buy ➝ Buy	$377.00 ➝ $478.00	+21.63%
7/30/2025	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Martin Auster Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform ➝ Outperform	$370.00	+11.93%
7/21/2025	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Danielle Brill Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$385.00	+20.11%
7/16/2025	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Jessica Fye Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Overweight ➝ Overweight	$338.00 ➝ $348.00	+11.85%
7/11/2025	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	David Lebovitz Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Buy ➝ Buy	$364.00 ➝ $404.00	+27.91%
7/11/2025	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Tazeen Ahmad Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Buy ➝ Buy	$336.00 ➝ $359.00	+11.27%
7/7/2025	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Maury Raycroft Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Buy ➝ Buy	$328.00 ➝ $384.00	+18.58%
6/24/2025	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Kostas Biliouris Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Outperform ➝ Outperform	$300.00 ➝ $360.00	+11.37%
4/2/2025	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Patrick Trucchio Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$500.00 ➝ $500.00	+91.04%
3/31/2025	Redburn Atlantic Subscribe to MarketBeat All Access for the recommendation accuracy rating	Joshua Smith Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$353.00	+31.49%
3/31/2025	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Paul Matteis Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Buy ➝ Buy	$300.00 ➝ $345.00	+28.51%
3/21/2025	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Luca Issi Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Outperform ➝ Outperform	$310.00 ➝ $330.00	+17.29%
3/21/2025	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Outperform
1/7/2025	Sanford C. Bernstein Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform ➝ Outperform	$314.00 ➝ $310.00	+31.53%
10/21/2024	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$282.00 ➝ $371.00	+25.37%
10/11/2024	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Neutral ➝ Neutral	$220.00 ➝ $220.00	-21.77%
8/16/2024	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	S. Richter Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$198.00 ➝ $370.00	+40.85%
6/25/2024	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Market Perform ➝ Market Perform	$138.00 ➝ $159.00	-33.15%
6/25/2024	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	L. Bayko Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Outperform ➝ Outperform	$210.00 ➝ $260.00	+12.40%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Monday at 10:56 AM ET.

Should I Buy Alnylam Pharmaceuticals Stock? ALNY Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Saturday, August 2, 2025. Please send any questions or comments about these Alnylam Pharmaceuticals pros and cons to contact@marketbeat.com.

Alnylam Pharmaceuticals
Bull Case

Here are some ways that investors could benefit from investing in Alnylam Pharmaceuticals, Inc.:

The current stock price is around $401.80, reflecting a strong market interest and potential for growth.
Alnylam Pharmaceuticals, Inc. reported a revenue increase of over 20% year-over-year, indicating strong business performance and demand for its products.
Institutional investors own approximately 92.97% of the company's stock, suggesting strong confidence from major financial players in the market.
The company has a solid current ratio of 3.04, which indicates good short-term financial health and the ability to cover its liabilities.
Recent insider trading activity, including significant sales by the CEO, may indicate a strategic repositioning that could benefit the company in the long run.

Alnylam Pharmaceuticals
Bear Case

Investors should be bearish about investing in Alnylam Pharmaceuticals, Inc. for these reasons:

The company has a high debt-to-equity ratio of 8.88, which may raise concerns about financial leverage and the ability to manage debt effectively.
Alnylam Pharmaceuticals, Inc. reported a negative return on equity of over 510%, indicating that the company is not currently generating profits relative to shareholder equity.
The stock has a P/E ratio that is negative, which can be a red flag for investors looking for profitability and growth potential.
Recent earnings reports showed that the company missed analysts' consensus estimates, which could indicate challenges in meeting market expectations.
Insider ownership is relatively low at 1.50%, which may suggest a lack of alignment between management and shareholder interests.

ALNY Forecast - Frequently Asked Questions

: According to the research reports of 27 Wall Street equities research analysts, the average twelve-month stock price forecast for Alnylam Pharmaceuticals is $396.04, with a high forecast of $550.00 and a low forecast of $220.00.
: 27 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Alnylam Pharmaceuticals in the last twelve months. There are currently 4 hold ratings and 23 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" ALNY shares.
: According to analysts, Alnylam Pharmaceuticals's stock has a predicted downside of -4.48% based on their 12-month stock forecasts.
: Over the previous 90 days, Alnylam Pharmaceuticals's stock had 2 upgrades by analysts.
: Alnylam Pharmaceuticals has been rated by research analysts at Bank of America, Barclays, BMO Capital Markets, Canaccord Genuity Group, Chardan Capital, Citigroup, Jefferies Financial Group, JPMorgan Chase & Co., Morgan Stanley, Needham & Company LLC, Oppenheimer, Piper Sandler, Raymond James Financial, Scotiabank, Truist Financial, UBS Group, Wells Fargo & Company, and Wolfe Research in the past 90 days.
: Analysts like Alnylam Pharmaceuticals more than other "medical" companies. The consensus rating score for Alnylam Pharmaceuticals is 2.85 while the average consensus rating score for "medical" companies is 2.81. Learn more on how ALNY compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top-Rated Stocks

More Ratings Tools

This page (NASDAQ:ALNY) was last updated on 8/4/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Alnylam Pharmaceuticals (ALNY) Stock Forecast & Price Target